Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest Diagnostics Inc.

www.questdiagnostics.com

Latest From Quest Diagnostics Inc.

Clinical Lab Group Gets Go-Ahead On Medicare Payment Suit

The American Clinical Laboratory Association (ACLA) may proceed with a lawsuit against the US Department of Health and Human Services, an appeals court has ruled. The suit alleges that the agency is setting lab test payment rates unfairly.

Reimbursement Diagnostics

Winning the Medtech Vs. Tech Battle: Five Lessons Learned From Tech’s Success

As medtech companies are fighting to protect their turf from innovative tech companies making their way into the traditional health-care space, there's also some important lessons to be learned from these newcomers. Raluca Cenusa and Brian Chapman of global sales and marketing consulting firm ZS Associates explain how medtech companies can use tech strategies to their advantage in building long-term relationships with customers, add value for customers, and use their accumulated wealth of patient data to build a treasure trove. This is the second installment of a three-part guest commentary series from ZS focusing on "defense strategies" to keep their tech rivals at bay.

Digital Health Business Strategies

Q3 Earnings Spotlight: Roche, Abbott, bioMérieux Lead IVD Company Results

Medtech Insight highlights Q3 2018 results from some of the leading IVD players. In this edition, we spotlight some of the big companies including Roche Diagnostics, Thermo Fisher Scientific, bioMérieux, and Becton Dickinson.

Commercial In Vitro Diagnostics

Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements

Approved two months after Alnylam’s Onpattro, Tegsedi is priced almost identically in the same hATTR indication. Ionis affiliate Akcea hopes weekly subcutaneous administration will provide convenience benefit compared to I.V. Onpattro.

Approvals Commercial
See All

Company Information

UsernamePublicRestriction

Register